121 results
424B5
ONCSQ
ONCOSEC MEDICAL Inc
18 May 23
Prospectus supplement for primary offering
9:30am
-oncology company focused on designing, developing and commercializing innovative, proprietary, intra-tumoral DNA-based therapeutics delivered … innovative, proprietary, intra-tumoral DNA-based therapeutics to stimulate and to augment anti-tumor immune responses for the treatment of cancers. Our core
424B5
ONCSQ
ONCOSEC MEDICAL Inc
11 Apr 23
Prospectus supplement for primary offering
10:40am
innovative, proprietary, intra-tumoral DNA-based therapeutics delivered by electroporation (“EP”) to stimulate and augment anti-tumor immune responses … , developing and commercializing innovative, proprietary, intra-tumoral DNA-based therapeutics to stimulate and to augment anti-tumor immune responses
424B3
ONCSQ
ONCOSEC MEDICAL Inc
1 Dec 22
Prospectus supplement
4:56pm
on designing, developing and commercializing innovative, proprietary, intra-tumoral DNA-based therapeutics delivered by electroporation (“EP … focused on designing, developing and commercializing innovative, proprietary, intra-tumoral DNA-based therapeutics to stimulate and to augment anti
8-K
rj8id7mmkc p2l56q9
29 Apr 22
OncoSec Appoints Dr. Robert Arch as President and Chief Executive Officer
8:00am
8-K
EX-99.1
luwu6knf
29 Apr 22
OncoSec Appoints Dr. Robert Arch as President and Chief Executive Officer
8:00am
8-K
f28bnoki79gx0 p2
22 Feb 22
OncoSec Announces Appointment of George Chi as Chief Financial Officer
5:22pm
8-K
EX-99.1
bg56sf2w9jqfpe8195f
22 Feb 22
OncoSec Announces Appointment of George Chi as Chief Financial Officer
5:22pm
8-K
hejk70
17 Dec 21
Departure of Directors or Certain Officers
9:27am